CA2904230A1 - Engager cells for immunotherapy - Google Patents

Info

Publication number

CA2904230A1

CA2904230A1 CA2904230A CA2904230A CA2904230A1 CA 2904230 A1 CA2904230 A1 CA 2904230A1 CA 2904230 A CA2904230 A CA 2904230A CA 2904230 A CA2904230 A CA 2904230A CA 2904230 A1 CA2904230 A1 CA 2904230A1

Authority

CA

Canada

Prior art keywords

cells

cell

epha2

engager

eng

Prior art date

2013-03-05

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Abandoned

Links

• Espacenet
• Global Dossier
• CIPO
• Discuss

• 238000009169 immunotherapy Methods 0.000 title claims abstract description 13
• 102000036639 antigens Human genes 0.000 claims abstract description 171
• 108091007433 antigens Proteins 0.000 claims abstract description 171
• 239000000427 antigen Substances 0.000 claims abstract description 170
• 206010028980 Neoplasm Diseases 0.000 claims abstract description 139
• 239000013598 vector Substances 0.000 claims abstract description 116
• 230000004913 activation Effects 0.000 claims abstract description 79
• 238000000034 method Methods 0.000 claims abstract description 64
• 201000011510 cancer Diseases 0.000 claims abstract description 61
• 210000004027 cell Anatomy 0.000 claims description 310
• 102100030340 Ephrin type-A receptor 2 Human genes 0.000 claims description 71
• 108010055196 EphA2 Receptor Proteins 0.000 claims description 69
• 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 41
• 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 39
• 102000040430 polynucleotide Human genes 0.000 claims description 39
• 108091033319 polynucleotide Proteins 0.000 claims description 39
• 239000002157 polynucleotide Substances 0.000 claims description 39
• 230000001177 retroviral effect Effects 0.000 claims description 36
• 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims description 35
• 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims description 35
• 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 19
• 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims description 19
• 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims description 19
• 239000012634 fragment Substances 0.000 claims description 18
• 239000013603 viral vector Substances 0.000 claims description 18
• 238000002512 chemotherapy Methods 0.000 claims description 10
• 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 9
• 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 9
• 230000003612 virological effect Effects 0.000 claims description 9
• 238000001356 surgical procedure Methods 0.000 claims description 8
• 238000011275 oncology therapy Methods 0.000 claims description 7
• 102100027207 CD27 antigen Human genes 0.000 claims description 5
• 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 5
• 238000001794 hormone therapy Methods 0.000 claims description 5
• 230000005855 radiation Effects 0.000 claims description 5
• 101150013553 CD40 gene Proteins 0.000 claims description 4
• 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 4
• 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims description 2
• 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 2
• 230000000174 oncolytic effect Effects 0.000 claims description 2
• 101000679851 Homo sapiens Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
• 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 1
• 210000002865 immune cell Anatomy 0.000 abstract description 64
• 239000000203 mixture Substances 0.000 abstract description 53
• 102000004127 Cytokines Human genes 0.000 abstract description 31
• 108090000695 Cytokines Proteins 0.000 abstract description 31
• 210000001744 T-lymphocyte Anatomy 0.000 description 387
• 238000002569 electronystagmography Methods 0.000 description 98
• 210000004881 tumor cell Anatomy 0.000 description 75
• 150000007523 nucleic acids Chemical class 0.000 description 72
• 230000014509 gene expression Effects 0.000 description 65
• 108090000765 processed proteins & peptides Proteins 0.000 description 64
• 102000039446 nucleic acids Human genes 0.000 description 49
• 108020004707 nucleic acids Proteins 0.000 description 49
• 108090000623 proteins and genes Proteins 0.000 description 45
• 210000000822 natural killer cell Anatomy 0.000 description 44
• 102000004196 processed proteins & peptides Human genes 0.000 description 43
• 241000699670 Mus sp. Species 0.000 description 37
• 108091008874 T cell receptors Proteins 0.000 description 33
• 230000027455 binding Effects 0.000 description 33
• 230000001105 regulatory effect Effects 0.000 description 33
• 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 32
• 229920001184 polypeptide Polymers 0.000 description 32
• 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 description 30
• 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 description 30
• 239000003795 chemical substances by application Substances 0.000 description 29
• 108010002350 Interleukin-2 Proteins 0.000 description 28
• 102000000588 Interleukin-2 Human genes 0.000 description 28
• 238000011282 treatment Methods 0.000 description 28
• 239000003446 ligand Substances 0.000 description 24
• 230000000259 anti-tumor effect Effects 0.000 description 23
• 102100037241 Endoglin Human genes 0.000 description 22
• 101000881679 Homo sapiens Endoglin Proteins 0.000 description 22
• 108090000172 Interleukin-15 Proteins 0.000 description 22
• 102000003812 Interleukin-15 Human genes 0.000 description 22
• 108091028043 Nucleic acid sequence Proteins 0.000 description 21
• 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 21
• 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 21
• YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 21
• 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 20
• 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 20
• 201000010099 disease Diseases 0.000 description 20
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 20
• 238000004519 manufacturing process Methods 0.000 description 20
• 210000001519 tissue Anatomy 0.000 description 20
• 239000013604 expression vector Substances 0.000 description 19
• 102000004169 proteins and genes Human genes 0.000 description 19
• 108020004414 DNA Proteins 0.000 description 18
• 239000003623 enhancer Substances 0.000 description 18
• 230000006870 function Effects 0.000 description 18
• 239000008194 pharmaceutical composition Substances 0.000 description 18
• -1 CCL1 Proteins 0.000 description 17
• 241001465754 Metazoa Species 0.000 description 17
• 230000006044 T cell activation Effects 0.000 description 17
• 241000700605 Viruses Species 0.000 description 17
• 230000000981 bystander Effects 0.000 description 16
• 230000000694 effects Effects 0.000 description 15
• 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 14
• 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 14
• 238000003556 assay Methods 0.000 description 14
• 102000005962 receptors Human genes 0.000 description 14
• 108020003175 receptors Proteins 0.000 description 14
• 230000003248 secreting effect Effects 0.000 description 14
• 102100038078 CD276 antigen Human genes 0.000 description 13
• 238000013518 transcription Methods 0.000 description 13
• 230000035897 transcription Effects 0.000 description 13
• 101000884279 Homo sapiens CD276 antigen Proteins 0.000 description 12
• 150000001413 amino acids Chemical group 0.000 description 12
• 230000029918 bioluminescence Effects 0.000 description 12
• 238000005415 bioluminescence Methods 0.000 description 12
• 230000000875 corresponding effect Effects 0.000 description 12
• 238000007912 intraperitoneal administration Methods 0.000 description 12
• 239000013612 plasmid Substances 0.000 description 12
• 230000003389 potentiating effect Effects 0.000 description 12
• 150000001875 compounds Chemical class 0.000 description 11
• 238000003384 imaging method Methods 0.000 description 11
• 238000001727 in vivo Methods 0.000 description 11
• 238000002347 injection Methods 0.000 description 11
• 239000007924 injection Substances 0.000 description 11
• 230000008569 process Effects 0.000 description 11
• 241001430294 unidentified retrovirus Species 0.000 description 11
• 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 description 10
• 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 description 10
• 239000003814 drug Substances 0.000 description 10
• 108010021843 fluorescent protein 583 Proteins 0.000 description 10
• 230000003993 interaction Effects 0.000 description 10
• 210000000581 natural killer T-cell Anatomy 0.000 description 10
• 230000028327 secretion Effects 0.000 description 10
• 230000008685 targeting Effects 0.000 description 10
• 238000010361 transduction Methods 0.000 description 10
• 230000026683 transduction Effects 0.000 description 10
• 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 9
• 238000013459 approach Methods 0.000 description 9
• 230000001419 dependent effect Effects 0.000 description 9
• 239000012636 effector Substances 0.000 description 9
• 108010087914 epidermal growth factor receptor VIII Proteins 0.000 description 9
• 230000001965 increasing effect Effects 0.000 description 9
• 230000000977 initiatory effect Effects 0.000 description 9
• 238000002560 therapeutic procedure Methods 0.000 description 9
• 108010004222 Natural Cytotoxicity Triggering Receptor 3 Proteins 0.000 description 8
• 102100032852 Natural cytotoxicity triggering receptor 3 Human genes 0.000 description 8
• 229940079593 drug Drugs 0.000 description 8
• 210000003527 eukaryotic cell Anatomy 0.000 description 8
• 230000002401 inhibitory effect Effects 0.000 description 8
• 208000020816 lung neoplasm Diseases 0.000 description 8
• 239000003550 marker Substances 0.000 description 8
• 210000002901 mesenchymal stem cell Anatomy 0.000 description 8
• 230000002265 prevention Effects 0.000 description 8
• 206010021143 Hypoxia Diseases 0.000 description 7
• 230000004663 cell proliferation Effects 0.000 description 7
• 238000002659 cell therapy Methods 0.000 description 7
• 239000003153 chemical reaction reagent Substances 0.000 description 7
• 230000001225 therapeutic effect Effects 0.000 description 7
• 241000701161 unidentified adenovirus Species 0.000 description 7
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
• 241000894006 Bacteria Species 0.000 description 6
• 108091026890 Coding region Proteins 0.000 description 6
• 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 6
• 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 6
• 108010002586 Interleukin-7 Proteins 0.000 description 6
• 102000000704 Interleukin-7 Human genes 0.000 description 6
• 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 6
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 6
• 230000008901 benefit Effects 0.000 description 6
• 238000002648 combination therapy Methods 0.000 description 6
• 230000000139 costimulatory effect Effects 0.000 description 6
• 238000002784 cytotoxicity assay Methods 0.000 description 6
• 231100000263 cytotoxicity test Toxicity 0.000 description 6
• 230000007423 decrease Effects 0.000 description 6
• 230000007954 hypoxia Effects 0.000 description 6
• 239000012642 immune effector Substances 0.000 description 6
• 229940121354 immunomodulator Drugs 0.000 description 6
• 230000001939 inductive effect Effects 0.000 description 6
• 239000003112 inhibitor Substances 0.000 description 6
• 230000005764 inhibitory process Effects 0.000 description 6
• 201000005202 lung cancer Diseases 0.000 description 6
• 230000004048 modification Effects 0.000 description 6
• 238000012986 modification Methods 0.000 description 6
• 238000004806 packaging method and process Methods 0.000 description 6
• 208000024891 symptom Diseases 0.000 description 6
• 230000009885 systemic effect Effects 0.000 description 6
• 230000002103 transcriptional effect Effects 0.000 description 6
• 102000019034 Chemokines Human genes 0.000 description 5
• 108010012236 Chemokines Proteins 0.000 description 5
• 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 5
• 238000002965 ELISA Methods 0.000 description 5
• 241000588724 Escherichia coli Species 0.000 description 5
• 208000002250 Hematologic Neoplasms Diseases 0.000 description 5
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 5
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 5
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
• 238000011198 co-culture assay Methods 0.000 description 5
• 238000010276 construction Methods 0.000 description 5
• 210000003958 hematopoietic stem cell Anatomy 0.000 description 5
• 230000003463 hyperproliferative effect Effects 0.000 description 5
• 230000002519 immonomodulatory effect Effects 0.000 description 5
• 230000004073 interleukin-2 production Effects 0.000 description 5
• 238000001990 intravenous administration Methods 0.000 description 5
• 208000032839 leukemia Diseases 0.000 description 5
• 210000004962 mammalian cell Anatomy 0.000 description 5
• 230000001537 neural effect Effects 0.000 description 5
• 230000002688 persistence Effects 0.000 description 5
• 238000001959 radiotherapy Methods 0.000 description 5
• 230000009467 reduction Effects 0.000 description 5
• 108091008146 restriction endonucleases Proteins 0.000 description 5
• 210000000130 stem cell Anatomy 0.000 description 5
• 230000000638 stimulation Effects 0.000 description 5
• 230000004083 survival effect Effects 0.000 description 5
• 238000001890 transfection Methods 0.000 description 5
• 238000012546 transfer Methods 0.000 description 5
• 238000013519 translation Methods 0.000 description 5
• 230000004614 tumor growth Effects 0.000 description 5
• 102100025221 CD70 antigen Human genes 0.000 description 4
• 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 4
• 241000196324 Embryophyta Species 0.000 description 4
• 102000010956 Glypican Human genes 0.000 description 4
• 108050001154 Glypican Proteins 0.000 description 4
• 108050007237 Glypican-3 Proteins 0.000 description 4
• 101000934356 Homo sapiens CD70 antigen Proteins 0.000 description 4
• 101001005728 Homo sapiens Melanoma-associated antigen 1 Proteins 0.000 description 4
• 101001057131 Homo sapiens Melanoma-associated antigen D4 Proteins 0.000 description 4
• 108060003951 Immunoglobulin Proteins 0.000 description 4
• 108060001084 Luciferase Proteins 0.000 description 4
• 239000005089 Luciferase Substances 0.000 description 4
• 102100025050 Melanoma-associated antigen 1 Human genes 0.000 description 4
• 101710089372 Programmed cell death protein 1 Proteins 0.000 description 4
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 4
• 108091023040 Transcription factor Proteins 0.000 description 4
• 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 description 4
• 230000003213 activating effect Effects 0.000 description 4
• 238000010171 animal model Methods 0.000 description 4
• 239000007864 aqueous solution Substances 0.000 description 4
• 230000001580 bacterial effect Effects 0.000 description 4
• 230000022534 cell killing Effects 0.000 description 4
• 238000010367 cloning Methods 0.000 description 4
• 238000003235 crystal violet staining Methods 0.000 description 4
• 230000001461 cytolytic effect Effects 0.000 description 4
• 239000003937 drug carrier Substances 0.000 description 4
• 239000000839 emulsion Substances 0.000 description 4
• 238000002474 experimental method Methods 0.000 description 4
• 238000012239 gene modification Methods 0.000 description 4
• 230000002068 genetic effect Effects 0.000 description 4
• 230000005017 genetic modification Effects 0.000 description 4
• 235000013617 genetically modified food Nutrition 0.000 description 4
• 208000005017 glioblastoma Diseases 0.000 description 4
• 230000012010 growth Effects 0.000 description 4
• 102000018358 immunoglobulin Human genes 0.000 description 4
• 238000001802 infusion Methods 0.000 description 4
• 230000002147 killing effect Effects 0.000 description 4
• 230000000670 limiting effect Effects 0.000 description 4
• 125000003729 nucleotide group Chemical group 0.000 description 4
• 239000002245 particle Substances 0.000 description 4
• 239000002953 phosphate buffered saline Substances 0.000 description 4
• 239000013600 plasmid vector Substances 0.000 description 4
• 238000000746 purification Methods 0.000 description 4
• 230000010076 replication Effects 0.000 description 4
• 238000010186 staining Methods 0.000 description 4
• 239000000126 substance Substances 0.000 description 4
• 238000011144 upstream manufacturing Methods 0.000 description 4
• 108010082808 4-1BB Ligand Proteins 0.000 description 3
• 102100023990 60S ribosomal protein L17 Human genes 0.000 description 3
• 102000006306 Antigen Receptors Human genes 0.000 description 3
• 108010083359 Antigen Receptors Proteins 0.000 description 3
• 108010074708 B7-H1 Antigen Proteins 0.000 description 3
• 206010006187 Breast cancer Diseases 0.000 description 3
• 208000026310 Breast neoplasm Diseases 0.000 description 3
• 102100021943 C-C motif chemokine 2 Human genes 0.000 description 3
• 102100032367 C-C motif chemokine 5 Human genes 0.000 description 3
• 108010055166 Chemokine CCL5 Proteins 0.000 description 3
• 102100028757 Chondroitin sulfate proteoglycan 4 Human genes 0.000 description 3
• 102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 description 3
• 101710091045 Envelope protein Proteins 0.000 description 3
• 208000032612 Glial tumor Diseases 0.000 description 3
• 206010018338 Glioma Diseases 0.000 description 3
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
• 101000916489 Homo sapiens Chondroitin sulfate proteoglycan 4 Proteins 0.000 description 3
• 241000713666 Lentivirus Species 0.000 description 3
• 231100000070 MTS assay Toxicity 0.000 description 3
• 238000000719 MTS assay Methods 0.000 description 3
• 241000699666 Mus <mouse, genus> Species 0.000 description 3
• 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 3
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
• 206010060862 Prostate cancer Diseases 0.000 description 3
• 108010076504 Protein Sorting Signals Proteins 0.000 description 3
• 101710188315 Protein X Proteins 0.000 description 3
• 238000011529 RT qPCR Methods 0.000 description 3
• 108091081024 Start codon Proteins 0.000 description 3
• 102000040945 Transcription factor Human genes 0.000 description 3
• 108010079206 V-Set Domain-Containing T-Cell Activation Inhibitor 1 Proteins 0.000 description 3
• 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 description 3
• 239000002246 antineoplastic agent Substances 0.000 description 3
• 210000003719 b-lymphocyte Anatomy 0.000 description 3
• 239000000872 buffer Substances 0.000 description 3
• 230000021164 cell adhesion Effects 0.000 description 3
• 230000030833 cell death Effects 0.000 description 3
• 230000001413 cellular effect Effects 0.000 description 3
• 230000000973 chemotherapeutic effect Effects 0.000 description 3
• 238000011260 co-administration Methods 0.000 description 3
• 208000029742 colonic neoplasm Diseases 0.000 description 3
• 238000012258 culturing Methods 0.000 description 3
• 238000011498 curative surgery Methods 0.000 description 3
• 239000008121 dextrose Substances 0.000 description 3
• 238000005516 engineering process Methods 0.000 description 3
• 230000001605 fetal effect Effects 0.000 description 3
• 238000009472 formulation Methods 0.000 description 3
• 108020001507 fusion proteins Proteins 0.000 description 3
• 102000037865 fusion proteins Human genes 0.000 description 3
• 238000001415 gene therapy Methods 0.000 description 3
• 238000010353 genetic engineering Methods 0.000 description 3
• 210000005260 human cell Anatomy 0.000 description 3
• 230000001506 immunosuppresive effect Effects 0.000 description 3
• 238000000338 in vitro Methods 0.000 description 3
• 230000010354 integration Effects 0.000 description 3
• 238000007917 intracranial administration Methods 0.000 description 3
• 238000010253 intravenous injection Methods 0.000 description 3
• 239000002502 liposome Substances 0.000 description 3
• 238000003670 luciferase enzyme activity assay Methods 0.000 description 3
• 239000000463 material Substances 0.000 description 3
• 238000010369 molecular cloning Methods 0.000 description 3
• 239000002773 nucleotide Substances 0.000 description 3
• 239000000843 powder Substances 0.000 description 3
• 210000001236 prokaryotic cell Anatomy 0.000 description 3
• 230000035755 proliferation Effects 0.000 description 3
• 238000002271 resection Methods 0.000 description 3
• 210000003705 ribosome Anatomy 0.000 description 3
• 230000011664 signaling Effects 0.000 description 3
• 239000011780 sodium chloride Substances 0.000 description 3
• 239000000243 solution Substances 0.000 description 3
• 230000006641 stabilisation Effects 0.000 description 3
• 238000011105 stabilization Methods 0.000 description 3
• 238000006467 substitution reaction Methods 0.000 description 3
• 238000012360 testing method Methods 0.000 description 3
• 241001515965 unidentified phage Species 0.000 description 3
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
• 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 2
• 102100038080 B-cell receptor CD22 Human genes 0.000 description 2
• 102100032912 CD44 antigen Human genes 0.000 description 2
• 108010058905 CD44v6 antigen Proteins 0.000 description 2
• 102100024423 Carbonic anhydrase 9 Human genes 0.000 description 2
• 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 2
• 102000000844 Cell Surface Receptors Human genes 0.000 description 2
• 108010001857 Cell Surface Receptors Proteins 0.000 description 2
• 206010009944 Colon cancer Diseases 0.000 description 2
• 102000053602 DNA Human genes 0.000 description 2
• 241000702421 Dependoparvovirus Species 0.000 description 2
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
• 101150076616 EPHA2 gene Proteins 0.000 description 2
• 101150039808 Egfr gene Proteins 0.000 description 2
• 102000004190 Enzymes Human genes 0.000 description 2
• 108090000790 Enzymes Proteins 0.000 description 2
• 102000050554 Eph Family Receptors Human genes 0.000 description 2
• 108091008815 Eph receptors Proteins 0.000 description 2
• 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 2
• 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 2
• 102100038595 Estrogen receptor Human genes 0.000 description 2
• 206010015548 Euthanasia Diseases 0.000 description 2
• 102000016621 Focal Adhesion Protein-Tyrosine Kinases Human genes 0.000 description 2
• 108010067715 Focal Adhesion Protein-Tyrosine Kinases Proteins 0.000 description 2
• 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 2
• 102000005720 Glutathione transferase Human genes 0.000 description 2
• 108010070675 Glutathione transferase Proteins 0.000 description 2
• 239000004471 Glycine Substances 0.000 description 2
• 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 2
• 108010075704 HLA-A Antigens Proteins 0.000 description 2
• 108010074032 HLA-A2 Antigen Proteins 0.000 description 2
• 102000025850 HLA-A2 Antigen Human genes 0.000 description 2
• 108010086377 HLA-A3 Antigen Proteins 0.000 description 2
• 241000282412 Homo Species 0.000 description 2
• 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 2
• 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 2
• 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 2
• 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 description 2
• 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 description 2
• 101000938346 Homo sapiens Ephrin type-A receptor 2 Proteins 0.000 description 2
• 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 2
• 101001055222 Homo sapiens Interleukin-8 Proteins 0.000 description 2
• 101001136592 Homo sapiens Prostate stem cell antigen Proteins 0.000 description 2
• 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 2
• 241000725303 Human immunodeficiency virus Species 0.000 description 2
• 101150106931 IFNG gene Proteins 0.000 description 2
• 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 2
• 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 2
• SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
• 108090000174 Interleukin-10 Proteins 0.000 description 2
• 102000003814 Interleukin-10 Human genes 0.000 description 2
• 108010065805 Interleukin-12 Proteins 0.000 description 2
• 102000013462 Interleukin-12 Human genes 0.000 description 2
• 102100026236 Interleukin-8 Human genes 0.000 description 2
• 208000008839 Kidney Neoplasms Diseases 0.000 description 2
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
• 206010025323 Lymphomas Diseases 0.000 description 2
• 102000003735 Mesothelin Human genes 0.000 description 2
• 108090000015 Mesothelin Proteins 0.000 description 2
• 102100029527 Natural cytotoxicity triggering receptor 3 ligand 1 Human genes 0.000 description 2
• 108010069196 Neural Cell Adhesion Molecules Proteins 0.000 description 2
• 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 2
• 102000004473 OX40 Ligand Human genes 0.000 description 2
• 108010042215 OX40 Ligand Proteins 0.000 description 2
• 102100021079 Ornithine decarboxylase Human genes 0.000 description 2
• 108700005126 Ornithine decarboxylases Proteins 0.000 description 2
• 102000036673 PRAME Human genes 0.000 description 2
• 108060006580 PRAME Proteins 0.000 description 2
• 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
• 108091093037 Peptide nucleic acid Proteins 0.000 description 2
• 102100023832 Prolyl endopeptidase FAP Human genes 0.000 description 2
• 102100036735 Prostate stem cell antigen Human genes 0.000 description 2
• 108010072866 Prostate-Specific Antigen Proteins 0.000 description 2
• 102100038358 Prostate-specific antigen Human genes 0.000 description 2
• 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
• 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
• 206010038389 Renal cancer Diseases 0.000 description 2
• 108091027981 Response element Proteins 0.000 description 2
• 208000003837 Second Primary Neoplasms Diseases 0.000 description 2
• 208000000453 Skin Neoplasms Diseases 0.000 description 2
• 208000005718 Stomach Neoplasms Diseases 0.000 description 2
• 108700026226 TATA Box Proteins 0.000 description 2
• NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
• 239000004098 Tetracycline Substances 0.000 description 2
• 208000024770 Thyroid neoplasm Diseases 0.000 description 2
• GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
• 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 2
• 241000700618 Vaccinia virus Species 0.000 description 2
• RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
• SRHNADOZAAWYLV-XLMUYGLTSA-N alpha-L-Fucp-(1->2)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](NC(C)=O)[C@H](O)O[C@@H]2CO)O[C@H]2[C@H]([C@H](O)[C@H](O)[C@H](C)O2)O)O[C@H](CO)[C@H](O)[C@@H]1O SRHNADOZAAWYLV-XLMUYGLTSA-N 0.000 description 2
• 238000004458 analytical method Methods 0.000 description 2
• 210000004102 animal cell Anatomy 0.000 description 2
• 230000000890 antigenic effect Effects 0.000 description 2
• 230000001640 apoptogenic effect Effects 0.000 description 2
• 230000006907 apoptotic process Effects 0.000 description 2
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
• 210000004369 blood Anatomy 0.000 description 2
• 239000008280 blood Substances 0.000 description 2
• 210000000481 breast Anatomy 0.000 description 2
• 239000001506 calcium phosphate Substances 0.000 description 2
• 229910000389 calcium phosphate Inorganic materials 0.000 description 2
• 235000011010 calcium phosphates Nutrition 0.000 description 2
• 239000000969 carrier Substances 0.000 description 2
• 230000015556 catabolic process Effects 0.000 description 2
• 201000009909 cataract 6 multiple types Diseases 0.000 description 2
• 230000010261 cell growth Effects 0.000 description 2
• 230000008859 change Effects 0.000 description 2
• 238000007385 chemical modification Methods 0.000 description 2
• 238000003776 cleavage reaction Methods 0.000 description 2
• 238000003501 co-culture Methods 0.000 description 2
• 230000000052 comparative effect Effects 0.000 description 2
• 239000002299 complementary DNA Substances 0.000 description 2
• 238000007796 conventional method Methods 0.000 description 2
• 230000001086 cytosolic effect Effects 0.000 description 2
• 239000000824 cytostatic agent Substances 0.000 description 2
• 230000001085 cytostatic effect Effects 0.000 description 2
• 238000006731 degradation reaction Methods 0.000 description 2
• 238000011161 development Methods 0.000 description 2
• 230000018109 developmental process Effects 0.000 description 2
• 230000004069 differentiation Effects 0.000 description 2
• 238000012063 dual-affinity re-targeting Methods 0.000 description 2
• VLCYCQAOQCDTCN-UHFFFAOYSA-N eflornithine Chemical compound NCCCC(N)(C(F)F)C(O)=O VLCYCQAOQCDTCN-UHFFFAOYSA-N 0.000 description 2
• 108700004025 env Genes Proteins 0.000 description 2
• 108700021358 erbB-1 Genes Proteins 0.000 description 2
• 108010038795 estrogen receptors Proteins 0.000 description 2
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
• 210000003976 gap junction Anatomy 0.000 description 2
• 206010017758 gastric cancer Diseases 0.000 description 2
• 239000001963 growth medium Substances 0.000 description 2
• 210000000987 immune system Anatomy 0.000 description 2
• 230000003308 immunostimulating effect Effects 0.000 description 2
• 230000001024 immunotherapeutic effect Effects 0.000 description 2
• 239000000411 inducer Substances 0.000 description 2
• 208000015181 infectious disease Diseases 0.000 description 2
• 238000003780 insertion Methods 0.000 description 2
• 230000037431 insertion Effects 0.000 description 2
• 102000006495 integrins Human genes 0.000 description 2
• 108010044426 integrins Proteins 0.000 description 2
• 201000010982 kidney cancer Diseases 0.000 description 2
• JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
• 239000006193 liquid solution Substances 0.000 description 2
• 201000007270 liver cancer Diseases 0.000 description 2
• 208000014018 liver neoplasm Diseases 0.000 description 2
• 210000004072 lung Anatomy 0.000 description 2
• 230000036210 malignancy Effects 0.000 description 2
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
• 239000002609 medium Substances 0.000 description 2
• 108020004999 messenger RNA Proteins 0.000 description 2
• 229960000485 methotrexate Drugs 0.000 description 2
• 230000000813 microbial effect Effects 0.000 description 2
• 238000010232 migration assay Methods 0.000 description 2
• 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
• 210000003463 organelle Anatomy 0.000 description 2
• 230000008520 organization Effects 0.000 description 2
• 239000001301 oxygen Substances 0.000 description 2
• 229910052760 oxygen Inorganic materials 0.000 description 2
• 208000008443 pancreatic carcinoma Diseases 0.000 description 2
• 239000000546 pharmaceutical excipient Substances 0.000 description 2
• 229920001481 poly(stearyl methacrylate) Polymers 0.000 description 2
• 239000000047 product Substances 0.000 description 2
• 210000002307 prostate Anatomy 0.000 description 2
• 230000003439 radiotherapeutic effect Effects 0.000 description 2
• 238000010188 recombinant method Methods 0.000 description 2
• 230000006798 recombination Effects 0.000 description 2
• 238000005215 recombination Methods 0.000 description 2
• 238000011160 research Methods 0.000 description 2
• 230000007017 scission Effects 0.000 description 2
• 238000012216 screening Methods 0.000 description 2
• 230000035945 sensitivity Effects 0.000 description 2
• 230000019491 signal transduction Effects 0.000 description 2
• 201000000849 skin cancer Diseases 0.000 description 2
• 239000002904 solvent Substances 0.000 description 2
• 241000894007 species Species 0.000 description 2
• 238000007619 statistical method Methods 0.000 description 2
• 201000011549 stomach cancer Diseases 0.000 description 2
• 231100000617 superantigen Toxicity 0.000 description 2
• 239000000725 suspension Substances 0.000 description 2
• 101150047061 tag-72 gene Proteins 0.000 description 2
• 238000002626 targeted therapy Methods 0.000 description 2
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
• 229960002180 tetracycline Drugs 0.000 description 2
• 229930101283 tetracycline Natural products 0.000 description 2
• 235000019364 tetracycline Nutrition 0.000 description 2
• 150000003522 tetracyclines Chemical class 0.000 description 2
• 238000013169 thromboelastometry Methods 0.000 description 2
• 239000003053 toxin Substances 0.000 description 2
• 231100000765 toxin Toxicity 0.000 description 2
• 108700012359 toxins Proteins 0.000 description 2
• 230000009466 transformation Effects 0.000 description 2
• 230000001131 transforming effect Effects 0.000 description 2
• 238000004627 transmission electron microscopy Methods 0.000 description 2
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
• 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
• 230000003827 upregulation Effects 0.000 description 2
• 239000003981 vehicle Substances 0.000 description 2
• CXNPLSGKWMLZPZ-GIFSMMMISA-N (2r,3r,6s)-3-[[(3s)-3-amino-5-[carbamimidoyl(methyl)amino]pentanoyl]amino]-6-(4-amino-2-oxopyrimidin-1-yl)-3,6-dihydro-2h-pyran-2-carboxylic acid Chemical compound O1[C@@H](C(O)=O)[C@H](NC(=O)C[C@@H](N)CCN(C)C(N)=N)C=C[C@H]1N1C(=O)N=C(N)C=C1 CXNPLSGKWMLZPZ-GIFSMMMISA-N 0.000 description 1
• BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 description 1
• GMOGICAFJFPMNS-UHFFFAOYSA-N 4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1CN1CCNCCCNCCNCCC1 GMOGICAFJFPMNS-UHFFFAOYSA-N 0.000 description 1
• STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
• 239000013607 AAV vector Substances 0.000 description 1
• 108010012934 Albumin-Bound Paclitaxel Proteins 0.000 description 1
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
• 241001465318 Aspergillus terreus Species 0.000 description 1
• 108010008014 B-Cell Maturation Antigen Proteins 0.000 description 1
• 102000006942 B-Cell Maturation Antigen Human genes 0.000 description 1
• 101710117995 B-lymphocyte antigen CD19 Proteins 0.000 description 1
• 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
• MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
• 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 description 1
• 108010006654 Bleomycin Proteins 0.000 description 1
• 241000701822 Bovine papillomavirus Species 0.000 description 1
• 208000003174 Brain Neoplasms Diseases 0.000 description 1
• COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
• 108050005711 C Chemokine Proteins 0.000 description 1
• 102000017483 C chemokine Human genes 0.000 description 1
• 102100023700 C-C motif chemokine 16 Human genes 0.000 description 1
• 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
• 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 1
• 108700012439 CA9 Proteins 0.000 description 1
• 108010040471 CC Chemokines Proteins 0.000 description 1
• 102000001902 CC Chemokines Human genes 0.000 description 1
• 101710185679 CD276 antigen Proteins 0.000 description 1
• 102000049320 CD36 Human genes 0.000 description 1
• 108010045374 CD36 Antigens Proteins 0.000 description 1
• 102100035793 CD83 antigen Human genes 0.000 description 1
• 108010081635 CX3C Chemokines Proteins 0.000 description 1
• 102000004325 CX3C Chemokines Human genes 0.000 description 1
• 108050006947 CXC Chemokine Proteins 0.000 description 1
• 102000019388 CXC chemokine Human genes 0.000 description 1
• 101100372806 Caenorhabditis elegans vit-3 gene Proteins 0.000 description 1
• UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
• KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
• 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• 201000009030 Carcinoma Diseases 0.000 description 1
• 102000053642 Catalytic RNA Human genes 0.000 description 1
• 108090000994 Catalytic RNA Proteins 0.000 description 1
• 206010057248 Cell death Diseases 0.000 description 1
• 241001227713 Chiron Species 0.000 description 1
• 108010049048 Cholera Toxin Proteins 0.000 description 1
• 102000009016 Cholera Toxin Human genes 0.000 description 1
• 208000006332 Choriocarcinoma Diseases 0.000 description 1
• VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
• VYZAMTAEIAYCRO-BJUDXGSMSA-N Chromium-51 Chemical compound [51Cr] VYZAMTAEIAYCRO-BJUDXGSMSA-N 0.000 description 1
• 108020004705 Codon Proteins 0.000 description 1
• 102100035167 Coiled-coil domain-containing protein 54 Human genes 0.000 description 1
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
• 102100035298 Cytokine SCM-1 beta Human genes 0.000 description 1
• 241000701022 Cytomegalovirus Species 0.000 description 1
• WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
• 101150074155 DHFR gene Proteins 0.000 description 1
• 230000005778 DNA damage Effects 0.000 description 1
• 231100000277 DNA damage Toxicity 0.000 description 1
• 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 1
• 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
• 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
• 108010092160 Dactinomycin Proteins 0.000 description 1
• ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 1
• BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
• 102000012804 EPCAM Human genes 0.000 description 1
• 101150084967 EPCAM gene Proteins 0.000 description 1
• 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 1
• LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
• 206010014733 Endometrial cancer Diseases 0.000 description 1
• 206010014759 Endometrial neoplasm Diseases 0.000 description 1
• 108010042407 Endonucleases Proteins 0.000 description 1
• 102000004533 Endonucleases Human genes 0.000 description 1
• 102000051096 EphA2 Receptor Human genes 0.000 description 1
• 101710116743 Ephrin type-A receptor 2 Proteins 0.000 description 1
• YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
• 241000701959 Escherichia virus Lambda Species 0.000 description 1
• 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
• 102100029951 Estrogen receptor beta Human genes 0.000 description 1
• 241000206602 Eukaryota Species 0.000 description 1
• HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 1
• 108060002716 Exonuclease Proteins 0.000 description 1
• 108010087819 Fc receptors Proteins 0.000 description 1
• 102000009109 Fc receptors Human genes 0.000 description 1
• 102100037362 Fibronectin Human genes 0.000 description 1
• 102000002090 Fibronectin type III Human genes 0.000 description 1
• 108050009401 Fibronectin type III Proteins 0.000 description 1
• 108010067306 Fibronectins Proteins 0.000 description 1
• 108090000331 Firefly luciferases Proteins 0.000 description 1
• GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
• 241000712469 Fowl plague virus Species 0.000 description 1
• 102100020997 Fractalkine Human genes 0.000 description 1
• 101150094690 GAL1 gene Proteins 0.000 description 1
• 102000002464 Galactosidases Human genes 0.000 description 1
• 108010093031 Galactosidases Proteins 0.000 description 1
• 102100028501 Galanin peptides Human genes 0.000 description 1
• 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
• 101710088083 Glomulin Proteins 0.000 description 1
• 102000003886 Glycoproteins Human genes 0.000 description 1
• 108090000288 Glycoproteins Proteins 0.000 description 1
• BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
• 108010069236 Goserelin Proteins 0.000 description 1
• 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
• 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
• 208000031886 HIV Infections Diseases 0.000 description 1
• 206010066476 Haematological malignancy Diseases 0.000 description 1
• 241000238631 Hexapoda Species 0.000 description 1
• 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
• 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
• 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
• 101000978375 Homo sapiens C-C motif chemokine 16 Proteins 0.000 description 1
• 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 description 1
• 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 description 1
• 101100383038 Homo sapiens CD19 gene Proteins 0.000 description 1
• 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 1
• 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 1
• 101000910338 Homo sapiens Carbonic anhydrase 9 Proteins 0.000 description 1
• 101000737052 Homo sapiens Coiled-coil domain-containing protein 54 Proteins 0.000 description 1
• 101000804771 Homo sapiens Cytokine SCM-1 beta Proteins 0.000 description 1
• 101001010910 Homo sapiens Estrogen receptor beta Proteins 0.000 description 1
• 101000854520 Homo sapiens Fractalkine Proteins 0.000 description 1
• 101100121078 Homo sapiens GAL gene Proteins 0.000 description 1
• 101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 description 1
• 101000998146 Homo sapiens Interleukin-17A Proteins 0.000 description 1
• 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
• 101001034314 Homo sapiens Lactadherin Proteins 0.000 description 1
• 101000804764 Homo sapiens Lymphotactin Proteins 0.000 description 1
• 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
• 101100460850 Homo sapiens NCR3LG1 gene Proteins 0.000 description 1
• 101001051490 Homo sapiens Neural cell adhesion molecule L1 Proteins 0.000 description 1
• 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 description 1
• 101000829725 Homo sapiens Phospholipid hydroperoxide glutathione peroxidase Proteins 0.000 description 1
• 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 description 1
• 101001076732 Homo sapiens RNA-binding protein 27 Proteins 0.000 description 1
• 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 description 1
• 101001056234 Homo sapiens Sperm mitochondrial-associated cysteine-rich protein Proteins 0.000 description 1
• 101000824971 Homo sapiens Sperm surface protein Sp17 Proteins 0.000 description 1
• 101000633445 Homo sapiens Structural maintenance of chromosomes protein 2 Proteins 0.000 description 1
• 101000874179 Homo sapiens Syndecan-1 Proteins 0.000 description 1
• 101000638251 Homo sapiens Tumor necrosis factor ligand superfamily member 9 Proteins 0.000 description 1
• 101000607320 Homo sapiens UL16-binding protein 2 Proteins 0.000 description 1
• 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 1
• 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
• 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
• 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
• 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
• 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
• 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
• 206010062016 Immunosuppression Diseases 0.000 description 1
• 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 description 1
• 102100025390 Integrin beta-2 Human genes 0.000 description 1
• 102000006992 Interferon-alpha Human genes 0.000 description 1
• 108010047761 Interferon-alpha Proteins 0.000 description 1
• 102000003996 Interferon-beta Human genes 0.000 description 1
• 108090000467 Interferon-beta Proteins 0.000 description 1
• 102000008070 Interferon-gamma Human genes 0.000 description 1
• 108010074328 Interferon-gamma Proteins 0.000 description 1
• 102100033461 Interleukin-17A Human genes 0.000 description 1
• 102000004388 Interleukin-4 Human genes 0.000 description 1
• 108090000978 Interleukin-4 Proteins 0.000 description 1
• 102000000743 Interleukin-5 Human genes 0.000 description 1
• 108010002616 Interleukin-5 Proteins 0.000 description 1
• 102000015696 Interleukins Human genes 0.000 description 1
• 108010063738 Interleukins Proteins 0.000 description 1
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
• 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
• 239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
• 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
• 239000002067 L01XE06 - Dasatinib Substances 0.000 description 1
• 239000002136 L01XE07 - Lapatinib Substances 0.000 description 1
• 239000005536 L01XE08 - Nilotinib Substances 0.000 description 1
• 239000003798 L01XE11 - Pazopanib Substances 0.000 description 1
• 239000002145 L01XE14 - Bosutinib Substances 0.000 description 1
• 239000002146 L01XE16 - Crizotinib Substances 0.000 description 1
• 239000002138 L01XE21 - Regorafenib Substances 0.000 description 1
• 239000002176 L01XE26 - Cabozantinib Substances 0.000 description 1
• 102100039648 Lactadherin Human genes 0.000 description 1
• 108010000851 Laminin Receptors Proteins 0.000 description 1
• 102000002297 Laminin Receptors Human genes 0.000 description 1
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
• 102100020872 Leucyl-cystinyl aminopeptidase Human genes 0.000 description 1
• 206010050017 Lung cancer metastatic Diseases 0.000 description 1
• 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 1
• 102100035304 Lymphotactin Human genes 0.000 description 1
• 102000043129 MHC class I family Human genes 0.000 description 1
• 108091054437 MHC class I family Proteins 0.000 description 1
• 108091022912 Mannose-6-Phosphate Isomerase Proteins 0.000 description 1
• 102000018697 Membrane Proteins Human genes 0.000 description 1
• 108010052285 Membrane Proteins Proteins 0.000 description 1
• 206010027476 Metastases Diseases 0.000 description 1
• 101100261636 Methanothermobacter marburgensis (strain ATCC BAA-927 / DSM 2133 / JCM 14651 / NBRC 100331 / OCM 82 / Marburg) trpB2 gene Proteins 0.000 description 1
• 101710151805 Mitochondrial intermediate peptidase 1 Proteins 0.000 description 1
• 229930192392 Mitomycin Natural products 0.000 description 1
• PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
• 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
• NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
• ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
• 101710201161 Natural cytotoxicity triggering receptor 3 ligand 1 Proteins 0.000 description 1
• 229930193140 Neomycin Natural products 0.000 description 1
• 102100024964 Neural cell adhesion molecule L1 Human genes 0.000 description 1
• 241001028048 Nicola Species 0.000 description 1
• 238000000636 Northern blotting Methods 0.000 description 1
• 229940122060 Ornithine decarboxylase inhibitor Drugs 0.000 description 1
• 206010033128 Ovarian cancer Diseases 0.000 description 1
• 206010061535 Ovarian neoplasm Diseases 0.000 description 1
• 240000007019 Oxalis corniculata Species 0.000 description 1
• 229930012538 Paclitaxel Natural products 0.000 description 1
• 206010034016 Paronychia Diseases 0.000 description 1
• 108010087702 Penicillinase Proteins 0.000 description 1
• 108010081690 Pertussis Toxin Proteins 0.000 description 1
• 101710114878 Phospholipase A-2-activating protein Proteins 0.000 description 1
• 102100035362 Phosphomannomutase 2 Human genes 0.000 description 1
• 108091000080 Phosphotransferase Proteins 0.000 description 1
• 101100124346 Photorhabdus laumondii subsp. laumondii (strain DSM 15139 / CIP 105565 / TT01) hisCD gene Proteins 0.000 description 1
• 206010035226 Plasma cell myeloma Diseases 0.000 description 1
• 102100022427 Plasmalemma vesicle-associated protein Human genes 0.000 description 1
• 101710193105 Plasmalemma vesicle-associated protein Proteins 0.000 description 1
• 239000002202 Polyethylene glycol Substances 0.000 description 1
• 230000006819 RNA synthesis Effects 0.000 description 1
• 102100025873 RNA-binding protein 27 Human genes 0.000 description 1
• 238000011530 RNeasy Mini Kit Methods 0.000 description 1
• 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 description 1
• 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 description 1
• 102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 description 1
• 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 description 1
• 108020004511 Recombinant DNA Proteins 0.000 description 1
• 206010070308 Refractory cancer Diseases 0.000 description 1
• 208000007660 Residual Neoplasm Diseases 0.000 description 1
• 108010039491 Ricin Proteins 0.000 description 1
• 241000714474 Rous sarcoma virus Species 0.000 description 1
• 238000011579 SCID mouse model Methods 0.000 description 1
• 108010017324 STAT3 Transcription Factor Proteins 0.000 description 1
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
• 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 1
• 206010061934 Salivary gland cancer Diseases 0.000 description 1
• 229920002684 Sepharose Polymers 0.000 description 1
• 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 description 1
• 108010071390 Serum Albumin Proteins 0.000 description 1
• 102000007562 Serum Albumin Human genes 0.000 description 1
• 108010032838 Sialoglycoproteins Proteins 0.000 description 1
• 102000007365 Sialoglycoproteins Human genes 0.000 description 1
• 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 description 1
• 241000713311 Simian immunodeficiency virus Species 0.000 description 1
• 241000713877 Simian sarcoma-associated virus Species 0.000 description 1
• 241000700584 Simplexvirus Species 0.000 description 1
• 241000710960 Sindbis virus Species 0.000 description 1
• 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
• 238000002105 Southern blotting Methods 0.000 description 1
• 208000000277 Splenic Neoplasms Diseases 0.000 description 1
• 108010090804 Streptavidin Proteins 0.000 description 1
• 102100029540 Structural maintenance of chromosomes protein 2 Human genes 0.000 description 1
• 238000000692 Student's t-test Methods 0.000 description 1
• 108010002687 Survivin Proteins 0.000 description 1
• 102100035721 Syndecan-1 Human genes 0.000 description 1
• 101150057140 TACSTD1 gene Proteins 0.000 description 1
• NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 description 1
• 108010008125 Tenascin Proteins 0.000 description 1
• 102100038126 Tenascin Human genes 0.000 description 1
• 102100033740 Tenomodulin Human genes 0.000 description 1
• 108700009124 Transcription Initiation Site Proteins 0.000 description 1
• 108700019146 Transgenes Proteins 0.000 description 1
• 101800001690 Transmembrane protein gp41 Proteins 0.000 description 1
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
• 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 1
• 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 1
• 102100039094 Tyrosinase Human genes 0.000 description 1
• 108060008724 Tyrosinase Proteins 0.000 description 1
• 102100039989 UL16-binding protein 2 Human genes 0.000 description 1
• 108090000848 Ubiquitin Proteins 0.000 description 1
• 102000044159 Ubiquitin Human genes 0.000 description 1
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
• 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
• 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
• 101710145727 Viral Fc-gamma receptor-like protein UL119 Proteins 0.000 description 1
• 108700005077 Viral Genes Proteins 0.000 description 1
• 229940028652 abraxane Drugs 0.000 description 1
• RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 239000013543 active substance Substances 0.000 description 1
• 239000000654 additive Substances 0.000 description 1
• 230000001476 alcoholic effect Effects 0.000 description 1
• 108700025316 aldesleukin Proteins 0.000 description 1
• 229930013930 alkaloid Natural products 0.000 description 1
• 229940100198 alkylating agent Drugs 0.000 description 1
• 239000002168 alkylating agent Substances 0.000 description 1
• 230000004075 alteration Effects 0.000 description 1
• 229960000473 altretamine Drugs 0.000 description 1
• 229940126575 aminoglycoside Drugs 0.000 description 1
• 229960000723 ampicillin Drugs 0.000 description 1
• AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
• 230000003321 amplification Effects 0.000 description 1
• 239000003242 anti bacterial agent Substances 0.000 description 1
• 230000001093 anti-cancer Effects 0.000 description 1
• 230000000340 anti-metabolite Effects 0.000 description 1
• 230000000692 anti-sense effect Effects 0.000 description 1
• 229940088710 antibiotic agent Drugs 0.000 description 1
• 238000011319 anticancer therapy Methods 0.000 description 1
• 229940100197 antimetabolite Drugs 0.000 description 1
• 239000002256 antimetabolite Substances 0.000 description 1
• 239000004599 antimicrobial Substances 0.000 description 1
• 229940041181 antineoplastic drug Drugs 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 235000006708 antioxidants Nutrition 0.000 description 1
• 238000003782 apoptosis assay Methods 0.000 description 1
• 239000008365 aqueous carrier Substances 0.000 description 1
• 239000012736 aqueous medium Substances 0.000 description 1
• 239000003125 aqueous solvent Substances 0.000 description 1
• 210000001367 artery Anatomy 0.000 description 1
• 210000004507 artificial chromosome Anatomy 0.000 description 1
• 230000003305 autocrine Effects 0.000 description 1
• VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
• 239000011324 bead Substances 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• 229960002938 bexarotene Drugs 0.000 description 1
• 210000000013 bile duct Anatomy 0.000 description 1
• 239000011230 binding agent Substances 0.000 description 1
• 238000010170 biological method Methods 0.000 description 1
• 238000001574 biopsy Methods 0.000 description 1
• 229960002685 biotin Drugs 0.000 description 1
• 235000020958 biotin Nutrition 0.000 description 1
• 239000011616 biotin Substances 0.000 description 1
• CXNPLSGKWMLZPZ-UHFFFAOYSA-N blasticidin-S Natural products O1C(C(O)=O)C(NC(=O)CC(N)CCN(C)C(N)=N)C=CC1N1C(=O)N=C(N)C=C1 CXNPLSGKWMLZPZ-UHFFFAOYSA-N 0.000 description 1
• 229960001561 bleomycin Drugs 0.000 description 1
• OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
• 229960003008 blinatumomab Drugs 0.000 description 1
• 230000036770 blood supply Effects 0.000 description 1
• 230000037396 body weight Effects 0.000 description 1
• 229960001467 bortezomib Drugs 0.000 description 1
• GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
• 229960003736 bosutinib Drugs 0.000 description 1
• UBPYILGKFZZVDX-UHFFFAOYSA-N bosutinib Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCCN4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl UBPYILGKFZZVDX-UHFFFAOYSA-N 0.000 description 1
• 229960002092 busulfan Drugs 0.000 description 1
• 210000004899 c-terminal region Anatomy 0.000 description 1
• 229960001292 cabozantinib Drugs 0.000 description 1
• ONIQOQHATWINJY-UHFFFAOYSA-N cabozantinib Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 ONIQOQHATWINJY-UHFFFAOYSA-N 0.000 description 1
• 239000001110 calcium chloride Substances 0.000 description 1
• 229910001628 calcium chloride Inorganic materials 0.000 description 1
• BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
• VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
• 229940127093 camptothecin Drugs 0.000 description 1
• 238000002619 cancer immunotherapy Methods 0.000 description 1
• 150000001720 carbohydrates Chemical class 0.000 description 1
• 235000014633 carbohydrates Nutrition 0.000 description 1
• 229960004562 carboplatin Drugs 0.000 description 1
• 108010021331 carfilzomib Proteins 0.000 description 1
• 229960002438 carfilzomib Drugs 0.000 description 1
• BLMPQMFVWMYDKT-NZTKNTHTSA-N carfilzomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)[C@]1(C)OC1)NC(=O)CN1CCOCC1)CC1=CC=CC=C1 BLMPQMFVWMYDKT-NZTKNTHTSA-N 0.000 description 1
• 230000003197 catalytic effect Effects 0.000 description 1
• 210000001159 caudate nucleus Anatomy 0.000 description 1
• 238000004113 cell culture Methods 0.000 description 1
• 230000022131 cell cycle Effects 0.000 description 1
• 238000001516 cell proliferation assay Methods 0.000 description 1
• 230000005859 cell recognition Effects 0.000 description 1
• 230000010307 cell transformation Effects 0.000 description 1
• 238000005119 centrifugation Methods 0.000 description 1
• 201000010881 cervical cancer Diseases 0.000 description 1
• 238000012512 characterization method Methods 0.000 description 1
• 239000002738 chelating agent Substances 0.000 description 1
• 238000006243 chemical reaction Methods 0.000 description 1
• 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
• 229960004630 chlorambucil Drugs 0.000 description 1
• JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
• 229930002875 chlorophyll Natural products 0.000 description 1
• 235000019804 chlorophyll Nutrition 0.000 description 1
• ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
• 210000003763 chloroplast Anatomy 0.000 description 1
• 229910052804 chromium Inorganic materials 0.000 description 1
• 239000011651 chromium Substances 0.000 description 1
• 210000000349 chromosome Anatomy 0.000 description 1
• 229960004316 cisplatin Drugs 0.000 description 1
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
• 239000013599 cloning vector Substances 0.000 description 1
• 238000009096 combination chemotherapy Methods 0.000 description 1
• 230000002301 combined effect Effects 0.000 description 1
• 238000004891 communication Methods 0.000 description 1
• 230000000295 complement effect Effects 0.000 description 1
• 238000002591 computed tomography Methods 0.000 description 1
• 230000002596 correlated effect Effects 0.000 description 1
• 229960005061 crizotinib Drugs 0.000 description 1
• KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 description 1
• 230000009260 cross reactivity Effects 0.000 description 1
• 238000002681 cryosurgery Methods 0.000 description 1
• 229960004397 cyclophosphamide Drugs 0.000 description 1
• 108010057085 cytokine receptors Proteins 0.000 description 1
• 102000003675 cytokine receptors Human genes 0.000 description 1
• 230000009089 cytolysis Effects 0.000 description 1
• 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
• 229940127089 cytotoxic agent Drugs 0.000 description 1
• 231100000135 cytotoxicity Toxicity 0.000 description 1
• 230000003013 cytotoxicity Effects 0.000 description 1
• 229960000640 dactinomycin Drugs 0.000 description 1
• 230000006378 damage Effects 0.000 description 1
• 229960002448 dasatinib Drugs 0.000 description 1
• STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
• 229960000975 daunorubicin Drugs 0.000 description 1
• 230000003247 decreasing effect Effects 0.000 description 1
• 230000002950 deficient Effects 0.000 description 1
• 238000012217 deletion Methods 0.000 description 1
• 230000037430 deletion Effects 0.000 description 1
• 210000004443 dendritic cell Anatomy 0.000 description 1
• 238000001514 detection method Methods 0.000 description 1
• 239000003085 diluting agent Substances 0.000 description 1
• 238000006471 dimerization reaction Methods 0.000 description 1
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
• 230000009429 distress Effects 0.000 description 1
• VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
• 229960003668 docetaxel Drugs 0.000 description 1
• 229960004679 doxorubicin Drugs 0.000 description 1
• 239000003792 electrolyte Substances 0.000 description 1
• 238000004520 electroporation Methods 0.000 description 1
• 230000003028 elevating effect Effects 0.000 description 1
• 210000001671 embryonic stem cell Anatomy 0.000 description 1
• 238000001976 enzyme digestion Methods 0.000 description 1
• 208000037828 epithelial carcinoma Diseases 0.000 description 1
• 230000008029 eradication Effects 0.000 description 1
• 229960001433 erlotinib Drugs 0.000 description 1
• AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
• 201000004101 esophageal cancer Diseases 0.000 description 1
• LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
• 229940093471 ethyl oleate Drugs 0.000 description 1
• VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
• 238000011156 evaluation Methods 0.000 description 1
• 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
• 229960005167 everolimus Drugs 0.000 description 1
• 102000013165 exonuclease Human genes 0.000 description 1
• 230000002349 favourable effect Effects 0.000 description 1
• 238000000684 flow cytometry Methods 0.000 description 1
• 239000012530 fluid Substances 0.000 description 1
• 238000012632 fluorescent imaging Methods 0.000 description 1
• 229960002949 fluorouracil Drugs 0.000 description 1
• 238000010230 functional analysis Methods 0.000 description 1
• 230000002538 fungal effect Effects 0.000 description 1
• 230000004927 fusion Effects 0.000 description 1
• 108700004026 gag Genes Proteins 0.000 description 1
• 201000010175 gallbladder cancer Diseases 0.000 description 1
• XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
• 229960005277 gemcitabine Drugs 0.000 description 1
• SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
• 238000001476 gene delivery Methods 0.000 description 1
• 238000010363 gene targeting Methods 0.000 description 1
• 102000034356 gene-regulatory proteins Human genes 0.000 description 1
• 108091006104 gene-regulatory proteins Proteins 0.000 description 1
• 102000018146 globin Human genes 0.000 description 1
• 108060003196 globin Proteins 0.000 description 1
• 230000013595 glycosylation Effects 0.000 description 1
• 238000006206 glycosylation reaction Methods 0.000 description 1
• 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
• 239000005090 green fluorescent protein Substances 0.000 description 1
• 239000003102 growth factor Substances 0.000 description 1
• 201000010536 head and neck cancer Diseases 0.000 description 1
• 208000014829 head and neck neoplasm Diseases 0.000 description 1
• 230000036541 health Effects 0.000 description 1
• 201000005787 hematologic cancer Diseases 0.000 description 1
• 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
• 210000003494 hepatocyte Anatomy 0.000 description 1
• 229940022353 herceptin Drugs 0.000 description 1
• UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
• 101150113423 hisD gene Proteins 0.000 description 1
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
• 229940125697 hormonal agent Drugs 0.000 description 1
• 102000055277 human IL2 Human genes 0.000 description 1
• 230000001146 hypoxic effect Effects 0.000 description 1
• 229960001101 ifosfamide Drugs 0.000 description 1
• HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
• 229960003685 imatinib mesylate Drugs 0.000 description 1
• YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 1
• 230000005931 immune cell recruitment Effects 0.000 description 1
• 230000028993 immune response Effects 0.000 description 1
• 238000013394 immunophenotyping Methods 0.000 description 1
• 230000005917 in vivo anti-tumor Effects 0.000 description 1
• 238000011534 incubation Methods 0.000 description 1
• PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
• RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
• 210000004263 induced pluripotent stem cell Anatomy 0.000 description 1
• 230000006698 induction Effects 0.000 description 1
• 239000011261 inert gas Substances 0.000 description 1
• 230000001524 infective effect Effects 0.000 description 1
• 230000035990 intercellular signaling Effects 0.000 description 1
• 230000014828 interferon-gamma production Effects 0.000 description 1
• 238000001361 intraarterial administration Methods 0.000 description 1
• 230000003834 intracellular effect Effects 0.000 description 1
• 230000004068 intracellular signaling Effects 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000007913 intrathecal administration Methods 0.000 description 1
• 238000011835 investigation Methods 0.000 description 1
• BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
• 229960000318 kanamycin Drugs 0.000 description 1
• 229930027917 kanamycin Natural products 0.000 description 1
• SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
• 229930182823 kanamycin A Natural products 0.000 description 1
• 239000004310 lactic acid Substances 0.000 description 1
• 235000014655 lactic acid Nutrition 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 229960004891 lapatinib Drugs 0.000 description 1
• BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 1
• 238000011031 large-scale manufacturing process Methods 0.000 description 1
• 238000002430 laser surgery Methods 0.000 description 1
• 238000012417 linear regression Methods 0.000 description 1
• 238000001325 log-rank test Methods 0.000 description 1
• 230000007774 longterm Effects 0.000 description 1
• PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
• 229960004844 lovastatin Drugs 0.000 description 1
• QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
• 208000037841 lung tumor Diseases 0.000 description 1
• 210000004698 lymphocyte Anatomy 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• 230000003211 malignant effect Effects 0.000 description 1
• 239000011159 matrix material Substances 0.000 description 1
• 238000005259 measurement Methods 0.000 description 1
• 229960004961 mechlorethamine Drugs 0.000 description 1
• HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
• 230000001404 mediated effect Effects 0.000 description 1
• 229960001924 melphalan Drugs 0.000 description 1
• SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
• 210000004779 membrane envelope Anatomy 0.000 description 1
• 208000037819 metastatic cancer Diseases 0.000 description 1
• 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
• 244000005700 microbiome Species 0.000 description 1
• 210000003470 mitochondria Anatomy 0.000 description 1
• 229960004857 mitomycin Drugs 0.000 description 1
• KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
• 239000002991 molded plastic Substances 0.000 description 1
• 230000035772 mutation Effects 0.000 description 1
• 201000000050 myeloid neoplasm Diseases 0.000 description 1
• 229940086322 navelbine Drugs 0.000 description 1
• 230000001338 necrotic effect Effects 0.000 description 1
• 229960004927 neomycin Drugs 0.000 description 1
• 210000005170 neoplastic cell Anatomy 0.000 description 1
• 230000007971 neurological deficit Effects 0.000 description 1
• 229960001346 nilotinib Drugs 0.000 description 1
• HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 description 1
• 239000012457 nonaqueous media Substances 0.000 description 1
• 239000000346 nonvolatile oil Substances 0.000 description 1
• 238000003199 nucleic acid amplification method Methods 0.000 description 1
• 235000015097 nutrients Nutrition 0.000 description 1
• 239000003921 oil Substances 0.000 description 1
• 235000019198 oils Nutrition 0.000 description 1
• 238000006384 oligomerization reaction Methods 0.000 description 1
• 239000004006 olive oil Substances 0.000 description 1
• 235000008390 olive oil Nutrition 0.000 description 1
• 238000001543 one-way ANOVA Methods 0.000 description 1
• 210000000056 organ Anatomy 0.000 description 1
• 150000002895 organic esters Chemical class 0.000 description 1
• 239000002818 ornithine decarboxylase inhibitor Substances 0.000 description 1
• 229960001592 paclitaxel Drugs 0.000 description 1
• 238000011499 palliative surgery Methods 0.000 description 1
• 201000002528 pancreatic cancer Diseases 0.000 description 1
• 230000003076 paracrine Effects 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 230000001717 pathogenic effect Effects 0.000 description 1
• 230000001575 pathological effect Effects 0.000 description 1
• 230000007170 pathology Effects 0.000 description 1
• 229960000639 pazopanib Drugs 0.000 description 1
• CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 description 1
• 229950009506 penicillinase Drugs 0.000 description 1
• 102000014187 peptide receptors Human genes 0.000 description 1
• 108010011903 peptide receptors Proteins 0.000 description 1
• 230000010412 perfusion Effects 0.000 description 1
• 230000000737 periodic effect Effects 0.000 description 1
• 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
• 210000001322 periplasm Anatomy 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• 230000026731 phosphorylation Effects 0.000 description 1
• 238000006366 phosphorylation reaction Methods 0.000 description 1
• 102000020233 phosphotransferase Human genes 0.000 description 1
• 230000000704 physical effect Effects 0.000 description 1
• BLFWHYXWBKKRHI-JYBILGDPSA-N plap Chemical compound N([C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)[C@@H]1CCCN1C(=O)[C@H](CO)NC(=O)[C@@H](N)CCC(O)=O BLFWHYXWBKKRHI-JYBILGDPSA-N 0.000 description 1
• 108700004029 pol Genes Proteins 0.000 description 1
• 239000004417 polycarbonate Substances 0.000 description 1
• 229920000515 polycarbonate Polymers 0.000 description 1
• 229920001223 polyethylene glycol Polymers 0.000 description 1
• 230000037048 polymerization activity Effects 0.000 description 1
• 238000010837 poor prognosis Methods 0.000 description 1
• 239000011148 porous material Substances 0.000 description 1
• 239000013641 positive control Substances 0.000 description 1
• 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
• 230000001323 posttranslational effect Effects 0.000 description 1
• 229960000214 pralatrexate Drugs 0.000 description 1
• OGSBUKJUDHAQEA-WMCAAGNKSA-N pralatrexate Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CC(CC#C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OGSBUKJUDHAQEA-WMCAAGNKSA-N 0.000 description 1
• 238000001556 precipitation Methods 0.000 description 1
• 239000002243 precursor Substances 0.000 description 1
• 238000002360 preparation method Methods 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 210000004986 primary T-cell Anatomy 0.000 description 1
• 230000000861 pro-apoptotic effect Effects 0.000 description 1
• 229960000624 procarbazine Drugs 0.000 description 1
• CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
• 230000005522 programmed cell death Effects 0.000 description 1
• 230000000770 proinflammatory effect Effects 0.000 description 1
• 229940087463 proleukin Drugs 0.000 description 1
• 230000002062 proliferating effect Effects 0.000 description 1
• 230000001737 promoting effect Effects 0.000 description 1
• 230000004850 protein–protein interaction Effects 0.000 description 1
• 238000011002 quantification Methods 0.000 description 1
• 239000013608 rAAV vector Substances 0.000 description 1
• GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 1
• 229960004622 raloxifene Drugs 0.000 description 1
• 230000009257 reactivity Effects 0.000 description 1
• 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
• 238000003259 recombinant expression Methods 0.000 description 1
• 238000011084 recovery Methods 0.000 description 1
• 208000016691 refractory malignant neoplasm Diseases 0.000 description 1
• 229960004836 regorafenib Drugs 0.000 description 1
• FNHKPVJBJVTLMP-UHFFFAOYSA-N regorafenib Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 FNHKPVJBJVTLMP-UHFFFAOYSA-N 0.000 description 1
• 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
• 230000008439 repair process Effects 0.000 description 1
• 230000004044 response Effects 0.000 description 1
• 230000000717 retained effect Effects 0.000 description 1
• 108010056030 retronectin Proteins 0.000 description 1
• 238000012552 review Methods 0.000 description 1
• 108091092562 ribozyme Proteins 0.000 description 1
• OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 description 1
• 229960003452 romidepsin Drugs 0.000 description 1
• OHRURASPPZQGQM-UHFFFAOYSA-N romidepsin Natural products O1C(=O)C(C(C)C)NC(=O)C(=CC)NC(=O)C2CSSCCC=CC1CC(=O)NC(C(C)C)C(=O)N2 OHRURASPPZQGQM-UHFFFAOYSA-N 0.000 description 1
• 108010091666 romidepsin Proteins 0.000 description 1
• 150000003839 salts Chemical class 0.000 description 1
• 238000000926 separation method Methods 0.000 description 1
• 125000005630 sialyl group Chemical group 0.000 description 1
• 210000000813 small intestine Anatomy 0.000 description 1
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
• 229960003787 sorafenib Drugs 0.000 description 1
• 230000009870 specific binding Effects 0.000 description 1
• 201000002471 spleen cancer Diseases 0.000 description 1
• 230000010473 stable expression Effects 0.000 description 1
• 238000011301 standard therapy Methods 0.000 description 1
• 239000008174 sterile solution Substances 0.000 description 1
• 230000004936 stimulating effect Effects 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 229960001796 sunitinib Drugs 0.000 description 1
• WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
• 239000006228 supernatant Substances 0.000 description 1
• 238000011477 surgical intervention Methods 0.000 description 1
• 230000002459 sustained effect Effects 0.000 description 1
• 231100000057 systemic toxicity Toxicity 0.000 description 1
• 238000012353 t test Methods 0.000 description 1
• 229960001603 tamoxifen Drugs 0.000 description 1
• 230000002123 temporal effect Effects 0.000 description 1
• 201000002510 thyroid cancer Diseases 0.000 description 1
• 210000001685 thyroid gland Anatomy 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 231100000331 toxic Toxicity 0.000 description 1
• 230000002588 toxic effect Effects 0.000 description 1
• 230000005030 transcription termination Effects 0.000 description 1
• 230000014621 translational initiation Effects 0.000 description 1
• 230000032258 transport Effects 0.000 description 1
• 238000005829 trimerization reaction Methods 0.000 description 1
• 101150081616 trpB gene Proteins 0.000 description 1
• 101150111232 trpB-1 gene Proteins 0.000 description 1
• 102000003390 tumor necrosis factor Human genes 0.000 description 1
• 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
• 241001529453 unidentified herpesvirus Species 0.000 description 1
• 241000712461 unidentified influenza virus Species 0.000 description 1
• 230000002485 urinary effect Effects 0.000 description 1
• 229960005486 vaccine Drugs 0.000 description 1
• 235000015112 vegetable and seed oil Nutrition 0.000 description 1
• 239000008158 vegetable oil Substances 0.000 description 1
• GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 description 1
• 229960003862 vemurafenib Drugs 0.000 description 1
• 230000007998 vessel formation Effects 0.000 description 1
• 108700026220 vif Genes Proteins 0.000 description 1
• JXLYSJRDGCGARV-CFWMRBGOSA-N vinblastine Chemical compound C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-CFWMRBGOSA-N 0.000 description 1
• 229960003048 vinblastine Drugs 0.000 description 1
• 229960004528 vincristine Drugs 0.000 description 1
• OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
• OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
• CILBMBUYJCWATM-PYGJLNRPSA-N vinorelbine ditartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC CILBMBUYJCWATM-PYGJLNRPSA-N 0.000 description 1
• 210000002845 virion Anatomy 0.000 description 1
• 230000001018 virulence Effects 0.000 description 1
• WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 1
• 229960000237 vorinostat Drugs 0.000 description 1
• 230000004580 weight loss Effects 0.000 description 1
• 238000001262 western blot Methods 0.000 description 1
• 239000000080 wetting agent Substances 0.000 description 1
• 229940033942 zoladex Drugs 0.000 description 1